Endocyte’s cancer drug meets main goal in lung cancer study

(Reuters) – Endocyte Inc said its experimental cancer drug, when used in combination with an approved treatment, improved survival rates without the disease worsening in a mid-stage study on patients with recurrent non-small cell lung cancer. The trial tested the drug, vintafolide, in combination with a chemotherapy drug known as docetaxel in 199 patients who failed one prior treatment with chemotherapy.